Biolight (BOLT) AI Stock Analysis

• Market Cap: ₪24.51M
• Dividend Yield: N/A
• Average Volume (3M): 11.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: -46.97%
• EPS Growth: -127.67%
• Country: IL
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -67.20
• Shares Outstanding: 9,079,270
• 10 Day Avg. Volume: 7,448
• 30 Day Avg. Volume: 11,863
• PEG Ratio: -0.06
• Price to Book (P/B): 0.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: 262.00 ▼(-29.46% Downside)
• Action: Reiterated Date: 04/07/26
• Date: Action: Reiterated 04/07/26

The score is driven primarily by weak financial performance (minimal/zero revenue, sustained losses, and ongoing cash burn), with additional pressure from bearish technicals (price below key moving averages and negative MACD). Valuation is only modestly supportive because the negative P/E reflects unprofitable operations, and no dividend yield is provided.

Positive Factors

Low leverage

Consistently minimal debt materially reduces refinancing and solvency risk over the medium term. A low-leverage capital structure gives management flexibility to fund R&D or secure bridge financing without heavy interest burdens, improving survival odds during extended product development cycles.

Negative Factors

Revenue collapse

Dropping to zero revenue signals a pre‑commercial or disrupted business model with no internal cash generation. Over the medium term this prevents self‑funding of operations, increases dependency on external capital, and heightens execution risk tied to successful commercialization or milestone events.

Biolight Business Overview & Revenue Model

Company Description

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of produ...

Read more

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of produ...

How the Company Makes Money

null...

Biolight Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	219.00K	118.00K	63.00K	3.00K
Gross Profit	-544.00K	219.00K	118.00K	63.00K	3.00K
EBITDA	-14.66M	-7.75M	-10.60M	-8.03M	-1.31M
Net Income	-11.73M	-7.14M	-26.02M	-7.85M	382.00K
Balance Sheet
Total Assets	42.41M	34.12M	33.45M	57.01M	64.17M
Cash, Cash Equivalents and Short-Term Investments	23.65M	13.47M	8.64M	17.63M	33.71M
Total Debt	772.00K	599.00K	91.00K	527.00K	443.00K
Total Liabilities	2.24M	3.38M	3.15M	3.32M	2.75M
Stockholders Equity	34.40M	26.88M	29.78M	53.17M	60.70M
Cash Flow
Free Cash Flow	-10.86M	-11.02M	-10.99M	-9.64M	-10.65M
Operating Cash Flow	-10.85M	-10.99M	-9.58M	-9.54M	-10.03M
Investing Cash Flow	-16.17M	7.55M	-1.95M	-10.55M	13.48M
Financing Cash Flow	21.37M	7.98M	3.25M	-485.00K	915.00K

Biolight Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 371.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 371.4 is above the 20-day moving average (MA) of 303.04, above the 50-day MA of 331.49, and below the 200-day MA of 420.75, indicating a bearish trend. The MACD of -24.99 indicates Positive momentum. The RSI at 40.72 is Neutral, neither overbought nor oversold. The STOCH value of 72.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.

Biolight Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	48 Neutral	₪33.94M	-9.73	―	―	-42.69%	88.04%
BOLT	44 Neutral	₪24.51M	-1.78	―	―	-46.97%	-127.67%
PPBT	43 Neutral	₪18.58M	-0.13	―	―	―	89.32%
CANF	42 Neutral	₪22.39M	-1.46	―	―	―	―